Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 261-270 of 2766 for

Edit search filters
  1. A Study to Compare Whole Brain Radiotherapy and Memantine to Stereotactic Radiosurgery vs. Stereotactic Radiosurgery Alone to Treat Patients with Cancer That Has Spread to the Brain After Earlier Stereotactic Radiosurgery

    Jacksonville, FL

  2. A Study to Evaluate the Safety and Effectiveness of Metformin and Nelfinavir with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  3. Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

    Rochester, MN

  4. Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

    Rochester, MN, Jacksonville, FL

  5. Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

    Scottsdale/Phoenix, AZ

  6. Study of Pembrolizumab Combined with Decitabine and Pralatrexate in Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma

    Rochester, MN

  7. A Study to Evaluate Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

  8. A Study of FT 2102 in Participants with Advanced Solid Tumors and Gliomas with an IDH1 Mutation

    Jacksonville, FL

  9. Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

  10. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    Rochester, MN

.

Mayo Clinic Footer